Comparison of Recommendations: Natriuretic Peptides
Class III: No Benefit
Measurement of natriuretic peptides is not recommended for CHD risk assessment in asymptomatic adults (Di Angelantonio et al., 2009). (Level of Evidence: B)
Increased BNP or NT-proBNP concentrations are associated with increased mortality in the next 2 to 7 years in community-based populations. However, the benefits of therapy based on these measurements are uncertain. Measurement for CVD risk assessment in the primary prevention setting is unwarranted. (Classification of recommendation: III [against measurement], Level of evidence: B)
No recommendations provided.
AHRQ © 2012
Agency for Healthcare Research and Quality (AHRQ)
Cite this: Assessing Cardiovascular Risk: Guideline Synthesis - Medscape - Mar 01, 2012.